High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
PURPOSE: Standard treatments for neoplastic meningitis are only modestly effective and are associated with significant morbidity. Isolated reports suggest that concurrent systemic and intrathecal (i.t.) therapy may be more effective than i.t. therapy alone. We present our experience, which includes CSF and serum pharmacokinetic data, on the use of high-dose (HD) intravenous (i.v.) methotrexate (MTX) as the sole treatment for neoplastic meningitis. PATIENTS AND METHODS: Sixteen patients with solid-tumor neoplastic meningitis received one to four courses (mean, 2.3 courses) of HD (8 g/m2 over 4 hours) i.v. MTX and leucovorin rescue. Serum and CSF MTX concentrations were measured daily. Toxicity, response, and survival were retrospectively compared with a reference group of 15 patients treated with standard i.t. MTX during the same time interval. RESULTS: Peak methotrexate concentrations ranged from 3.7 to 55 micromol/L (mean, 17.1 micromol/L) in CSF and 178 to 1,700 micromol/L (mean, 779 micromol/L) in serum. Cytotoxic CSF and serum MTX concentrations were maintained much longer than with i.t. dosing. Toxicity was minimal. Cytologic clearing was seen in 81% of patients compared with 60% of patients treated intrathecally (P = .3). Median survival in the HD i.v. MTX group was 13.8 months versus 2.3 months in the i.t. MTX group (P = .003). CONCLUSION: HD i.v. MTX is easily administered and well tolerated. This regimen achieves prolonged cytotoxic serum MTX concentrations and CSF concentrations at least comparable to those achieved with standard i.t. therapy. Cytologic clearing and survival may be superior in patients treated with HD i.v. MTX. Prospective studies and a reconsideration of the use of i.t. chemotherapy for patients with neoplastic meningitis are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients
Wasserstrom, W. R., Glass, J. P., & Posner, J. B. (1982) · Cancer · doi:10.1002/1097-0142(19820215)49:4<759::aid-cncr2820490427>3.0.co;2-7 · Cited by 1,124
Shapiro, W. R., Young, D. F., & Mehta, B. M. (1975) · New England Journal of Medicine · doi:10.1056/nejm197507242930402 · Cited by 681
Cerebrospinal fluid cytology in patients with cancer: Minimizing false-negative results
Glantz, M. J., Cole, B. F., Glantz, L. K., Cobb, J., Mills, P., Lekos, A., Walters, B. C., & Recht, L. D. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980215)82:4<733::aid-cncr17>3.0.co;2-z · Cited by 456
Self-citationNeuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis
Freilich, R. J., Krol, G., & Deangelis, L. M. (1995) · Annals of Neurology · doi:10.1002/ana.410380111 · Cited by 412
Grossman, S. A., Finkelstein, D. M., Ruckdeschel, J. C., Trump, D. L., Moynihan, T., & Ettinger, D. S. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.561 · Cited by 364
Hitchins, R. N., Bell, D. R., Woods, R. L., & Levi, J. A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.10.1655 · Cited by 352
Chabner, B. A., & Young, R. C. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107362 · Cited by 236
Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment
Boogerd, W. J., Hart, A. A. M., van der Sande, J. J., & Engelsman, E. (1991) · Cancer · doi:10.1002/1097-0142(19910315)67:6<1685::aid-cncr2820670635>3.0.co;2-m · Cited by 204
Glantz, M., Hall, W. A., Cole, B. F., Chozick, B. S., Shannon, C., Wahlberg, L. U., Akerley, W., Marin, L., & Choy, H. (1995) · Cancer · doi:10.1002/1097-0142(19950615)75:12<2919::aid-cncr2820751220>3.0.co;2-9 · Cited by 195
Self-citation
Cited by
Le Rhun, E., Weller, M., Brandsma, D., Van den Bent, M., de Azambuja, E., Henriksson, R., Boulanger, T., Peters, S., Watts, C., Wick, W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx221 · Cited by 637
Grossman, S. A., & Krabak, M. J. (1999) · Cancer Treatment Reviews · doi:10.1053/ctrv.1999.0119 · Cited by 529
Aparicio, A., & Chamberlain, M. C. (2002) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-002-0081-7 · Cited by 487
Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check
Muldoon, L. L., Soussain, C., Jahnke, K., Johanson, C., Siegal, T., Smith, Q. R., Hall, W. A., Hynynen, K., Senter, P. D., Peereboom, D. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.9861 · Cited by 417
Carcinomatous meningitis: Leptomeningeal metastases in solid tumors
Chamberlain, M., Le Rhun, E., & Taillibert, S. (2013) · Surgical Neurology International · doi:10.4103/2152-7806.111304 · Cited by 338
Gleissner, B., & Chamberlain, M. C. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70443-4 · Cited by 277
Leptomeningeal metastasis from systemic cancer: Review and update on management
Wang, N., Bertalan, M. S., & Brastianos, P. K. (2018) · Cancer · doi:10.1002/cncr.30911 · Cited by 262
Chamberlain, M. C. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833de986 · Cited by 193
Oechsle, K., Lange-Brock, V., Kruell, A., Bokemeyer, C., & de Wit, M. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0831-x · Cited by 119
Metadata
- Authors
- Glantz, M. J., Cole, B. F., Recht, L., Akerley, W., Mills, P., Saris, S., Hochberg, F., Calabresi, P., & Egorin, M. J.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-04
- Volume
- 16
- Issue
- 4
- Pages
- 1561-1567
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1819450960
- Cited by
- 322
- References
- 21
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.